| Differential pharmacotherapy for subgroups of fibromyalgia patients with specific consideration of 5-HT3 receptor antagonists. | |
| | |
MedLine Citation:
|
PMID: 21323622 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
Introduction: The fibromyalgia syndrome (FMS) has a prevalence of about 2% and is characterized by generalized musculoskeletal pain, reduced pain threshold and autonomic and functional symptoms. It is a multifactorial syndrome with four different subgroups exhibiting pathophysiological and psychiatric findings. No precise treatment strategy is currently available for the different FMS subgroups. Areas covered: This article reviews the evidence for treatment options for the different FMS subgroups. Expert opinion: Therapy for the first subgroup of primary FMS, with high levels of pain but no psychopathological alterations, is targeted at nociceptors expressing serotonin (5-hydroxytryptamine-3; 5-HT3) receptors with 5-HT3 receptor antagonists. The second and third subgroups are characterized by depressive syndromes with a major indication for antidepressants. The fourth subgroup with psychosomatic syndromes requires psychotherapeutic treatment. Secondary FMS is similar to the primary syndromes but is triggered by a variety of other diseases and frequently responds to 5-HT3 receptor antagonist treatment. Different classes of drug, such as pregabalin, must be tested for efficacy and tolerance. FMS treatment strategies should be tailored after the identification of individual FMS subgroups. Although several groups of drug have been studied extensively, 5-HT3 receptor antagonists are most effective in patients without psychopathological alterations. |
| | |
Authors:
|
Matthias F Seidel; Wolfgang Müller |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2011-2-17 |
Journal Detail:
|
Title: Expert opinion on pharmacotherapy Volume: - ISSN: 1744-7666 ISO Abbreviation: - Publication Date: 2011 Feb |
Date Detail:
|
Created Date: 2011-2-17 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 100897346 Medline TA: Expert Opin Pharmacother Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Medizinische Klinik und Poliklinik I, Rheumatology Unit, Wilhelmstrasse 35-37, D-53111 Bonn, Germany +49 228 287 22263 ; +49 228 287 22025 ; Matthias.Seidel@ukb.uni-bonn.de. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Effectiveness of health and wellness initiatives for seniors.
Next Document: Evaluation of two HbA1c point-of-care analyzers.